All Institutions
Search all resources
Search for entire words only

Eslicarbazepine acetate, Monotherapy

BIAL - Portela & Cª, S.A.
Project classification

Scientific area

3.1 Basic medicine


Neurosciences (including psychophysiology)

Project description

Project title

Eslicarbazepine acetate, Monotherapy

Scientific Coordinator's name:

Prof. Patrício Soares-da-Silva

Scientific Coordinator's e-mail:

Principal R&D Unit:

Prof. Patrício Soares-da-Silva

Other R&D Units involved in the project:

Other R&D units involved in the project

Project keyword(s)

Eslicarbazepine acetate, Epilepsy, Monotherapy

Short abstract and comments

Given the efficacy of eslicarbazepine acetate in controlling partial-onset seizures, the good tolerability and the convenience of QD dosing instead of twice daily (BID) dosing, eslicarbazepine acetate could offer a beneficial alternative as a first-line therapy in patients newly diagnosed with epilepsy experiencing partial-onset seizures. Eslicarbazepine acetate is currently under development by BIAL - Portela & Cª, S.A. for the indication in monotherapy in patients with newly diagnosed partial-onset seizures. Study is being conducted in an estimated 170 centers in approximately 30 countries. This study aims to demonstrate the efficacy and safety of eslicarbazepine acetate as a monotherapy treatment.

Potential uses/indications




Partner Status: Seeking Partners?


Grant number (QREN, FP7, Eureka, etc)

QREN 4859

Last edited on

2011-11-09 14:16:56

Health Cluster Portugal All rights reserved
© 2024 Health Cluster Portugal All rights reserved